Consensus Teva Pharmaceutical Industries Limited OTC Markets

Equities

TEVJF

IL0006290147

Market Closed - OTC Markets Other stock markets 11:32:46 25/06/2024 pm IST			5-day change	1st Jan Change
14.7 ^USD	-18.33%		-18.33%	+70.53%

28/06	Teva Pharmaceutical Industries Ltd Announces New AJOVY® (Fremanezumab) Migraine Prevention Data Challenges Treatment Pauses	CI
27/06	Jefferies Adjusts Price Target on Teva Pharmaceutical Industries to $23 From $19, Maintains Buy Rating	MT

Evolution of the average Target Price on Teva Pharmaceutical Industries Limited

Price target over the last 5 years

History of analyst recommendation changes

582eb07dcbfcc965f872c37.lijwukiDE884fkc9zkfM7b4mKVSU57aKWNxxWofhSVk.4H2x0yXwWr0MHzdn_jC6mohIGGTdvtDMLo5BCMqoGCijXb73Ps5QuU0vMA~0a5038b492ed2b578bc453a696f343c8

Analyst Recommendations on Teva Pharmaceutical Industries Limited

Jefferies Adjusts Price Target on Teva Pharmaceutical Industries to $23 From $19, Maintains Buy Rating	27/06	MT
Teva Pharmaceutical Industries 'Well-Positioned' for Further Growth, UBS Says	21/06	MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $21 From $20, Maintains Overweight Rating	05/06	MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $470,794, According to a Recent SEC Filing	17/05	MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $254,807, According to a Recent SEC Filing	15/05	MT
Piper Sandler Adjusts Price Target on Teva Pharmaceutical Industries to $20 From $19, Maintains Overweight Rating	13/05	MT
JPMorgan Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Adjusts Price Target to $14 From $11	08/03	MT
Piper Sandler Upgrades Teva Pharmaceutical Industries to Overweight From Neutral, Adjusts PT to $19 From $12	12/02	MT
Goldman Sachs Adjusts Price Target on Teva Pharmaceutical Industries to $11 From $10, Maintains Neutral Rating	05/02	MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $17 From $15, Maintains Overweight Rating	05/02	MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $15 From $14, Maintains Overweight Rating	29/01	MT
Teva: share price up, broker in support	23/01	CF
TEVA : Jefferies raises its recommendation	23/01	CF
Jefferies Upgrades Teva Pharmaceutical Industries to Buy From Hold, Raises Price Target to $14 From $10	23/01	MT
BofA Securities Adjusts Teva Pharmaceutical Industries Price Target to $14 From $13, Maintains Buy Rating	12/01	MT
Piper Sandler Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Raises Price Target to $12 From $8	03/01	MT
HSBC Initiates Teva Pharmaceutical Industries at Buy Rating With $13 Price Target	18/12	MT
UBS Upgrades Teva Pharmaceutical Industries to Buy From Neutral, Adjusts Price Target to $13 From $11	27/11	MT
UBS Upgrades Teva Pharmaceutical Industries to Neutral From Sell, Raises Price Target to $8 From $7	06/23/06	MT
Evercore ISI Upgrades Teva Pharmaceutical Industries to Outperform From In-Line	18/23/18	MT
Barclays Adjusts Teva Pharmaceutical Industries Price Target to $14 From $13, Maintains Overweight Rating	09/23/09	MT
Jefferies Downgrades Teva Pharmaceutical Industries to Hold From Buy, Adjusts Price Target to $12 From $10	19/23/19	MT
UBS Downgrades Teva Pharmaceutical Industries to Sell From Neutral, Adjusts Price Target to $7 From $10	04/22/04	MT
Jefferies Assumes Teva Pharmaceutical Industries at Buy with $10 Price Target	21/22/21	MT
BofA Securities Adjusts Teva Pharmaceutical Industries Price Target to $11 From $13, Maintains Buy Rating	15/22/15	MT